Evotec Rides Megatrend In Outsourced Innovation By Buying Aptuit CRO

Evotec's CEO tells Scrip that by buying the CRO Aptuit his combined group becomes a one-stop-shop for drug makers who are increasingly outsourcing their innovation efforts.

3d one stop shop sign on white background
Evotec Aims To Be One-Stop-Shop For Therapy Innovation With Aptuit Buy • Source: Shutterstock

The increasing complexity of emerging technologies needed for drug discovery demands bigger players who can bring them together on one platform to optimize for best possible results. Evotec AG says that megatrend lies behind its purchase of the CRO Aptuit, creating a "one-stop-shop" for external innovation.

"The rationale behind this acquisition is to give everyone the option to go much faster on a very clear path...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.